Tags

Type your tag names separated by a space and hit enter

Novel role of the serine protease inhibitor elafin in gluten-related disorders.
Am J Gastroenterol. 2014 May; 109(5):748-56.AJ

Abstract

OBJECTIVES

Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity.

METHODS

Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with human tissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed.

RESULTS

Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression.

CONCLUSIONS

The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders.

Authors+Show Affiliations

Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.1] INSERM, U1043, Toulouse, France [2] CNRS, U5282, Toulouse, France [3] Université de Toulouse, Université Paul Sabatier, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, France.Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.1] INSERM, U1043, Toulouse, France [2] CNRS, U5282, Toulouse, France [3] Université de Toulouse, Université Paul Sabatier, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, France.Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, INRA, Jouy-en-Josas, France.Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, INRA, Jouy-en-Josas, France.Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland.Division of Gastroenterology and Hepatology, Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina.Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina.1] INSERM, U1043, Toulouse, France [2] CNRS, U5282, Toulouse, France [3] Université de Toulouse, Université Paul Sabatier, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, France.Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, INRA, Jouy-en-Josas, France.Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24710505

Citation

Galipeau, Heather J., et al. "Novel Role of the Serine Protease Inhibitor Elafin in Gluten-related Disorders." The American Journal of Gastroenterology, vol. 109, no. 5, 2014, pp. 748-56.
Galipeau HJ, Wiepjes M, Motta JP, et al. Novel role of the serine protease inhibitor elafin in gluten-related disorders. Am J Gastroenterol. 2014;109(5):748-56.
Galipeau, H. J., Wiepjes, M., Motta, J. P., Schulz, J. D., Jury, J., Natividad, J. M., Pinto-Sanchez, I., Sinclair, D., Rousset, P., Martin-Rosique, R., Bermudez-Humaran, L., Leroux, J. C., Murray, J. A., Smecuol, E., Bai, J. C., Vergnolle, N., Langella, P., & Verdu, E. F. (2014). Novel role of the serine protease inhibitor elafin in gluten-related disorders. The American Journal of Gastroenterology, 109(5), 748-56. https://doi.org/10.1038/ajg.2014.48
Galipeau HJ, et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-related Disorders. Am J Gastroenterol. 2014;109(5):748-56. PubMed PMID: 24710505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel role of the serine protease inhibitor elafin in gluten-related disorders. AU - Galipeau,Heather J, AU - Wiepjes,Michelle, AU - Motta,Jean-Paul, AU - Schulz,Jessica D, AU - Jury,Jennifer, AU - Natividad,Jane M, AU - Pinto-Sanchez,Ines, AU - Sinclair,Daniel, AU - Rousset,Perrine, AU - Martin-Rosique,Rebeca, AU - Bermudez-Humaran,Luis, AU - Leroux,Jean Christophe, AU - Murray,Joseph A, AU - Smecuol,Edgardo, AU - Bai,Julio C, AU - Vergnolle,Nathalie, AU - Langella,Philippe, AU - Verdu,Elena F, Y1 - 2014/04/08/ PY - 2013/11/22/received PY - 2014/02/02/accepted PY - 2014/4/9/entrez PY - 2014/4/9/pubmed PY - 2014/6/24/medline SP - 748 EP - 56 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 109 IS - 5 N2 - OBJECTIVES: Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity. METHODS: Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with human tissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed. RESULTS: Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression. CONCLUSIONS: The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders. SN - 1572-0241 UR - https://www.unboundmedicine.com/medline/citation/24710505/Novel_Role_of_the_Serine_Protease_Inhibitor_Elafin_in_Gluten_Related_Disorders_ L2 - https://Insights.ovid.com/pubmed?pmid=24710505 DB - PRIME DP - Unbound Medicine ER -